Navigation Links
United States Seizes Unapproved Ozone Generators
Date:1/29/2010

FDA inspection shows devices produced under poor manufacturing condition; pose public health risk

SILVER SPRING, Md., Jan. 29 /PRNewswire-USNewswire/ -- At the request of the U.S. Food and Drug Administration, U.S. Marshals today seized 77 ozone generators, models AOS-1M and AOS-1MD, from Applied Ozone Systems of Auburn, Calif. The seized goods, which are medical devices, are valued at $75,900.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

The FDA advises health care professionals and consumers to discontinue use of these devices, which Applied Ozone Systems claims can treat cancer, AIDS, hepatitis, herpes, and a number of other diseases and conditions. The FDA has not determined that the seized products are safe and effective in treating the diseases or conditions, and officials at Applied Ozone Systems never responded to a Dec. 21, 2009 FDA request for a voluntary recall of these ozone generators.

In addition, the agency is concerned that patients who use these AOS ozone devices as directed by the manufacturer may believe that ozone therapy serves as an appropriate treatment and as a result delay or stop conventional or prescribed effective treatment. There is also a risk of infection from potential contamination of the applicator or catheter.

The FDA inspected Applied Ozone Systems in October 2009 after obtaining an inspection warrant when the owner of the company refused to allow agency staff to inspect the facility. The agency's inspection revealed significant deviations from the FDA's current good manufacturing practice (GMP) requirements for medical devices, and confirmed that the company has not obtained FDA marketing approval or clearance for these devices. The unapproved status of these devices and the conditions under which they were manufactured cause them to be adulterated and misbranded.

Ozone generators are devices that produce ozone from oxygen. Ozone is present in low levels throughout the earth's atmosphere and has many industrial and consumer applications. It also is an air pollutant that has harmful effects on the respiratory system.

Ozone administration methods suggested by the manufacturer of the AOS-1M Medical Ozone Generator and the AOS-1MD Ozone Generator include blowing ozonized air into the rectal and vaginal areas.

"The seized devices are potentially harmful to public health," said Michael Chappell, the FDA's acting associate commissioner for regulatory affairs. "The agency will take action to protect the public from FDA-regulated products that are in violation of the law."

Today's seizure action was jointly conducted by the FDA and the State of California Department of Public Health, Food and Drug Branch as part of ongoing to efforts to ensure that unapproved medical devices that have not been found to be safe and effective do not enter the marketplace.

Health care professionals and consumers may report serious adverse events (side effects) or product quality problems with the use of these products to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail, fax or phone.


Media Inquiries: Tom Gasparoli, 301-796-4737, thomas.gasparoli@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration

RELATED LINKS
http://www.fda.gov/

'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. R-CALF United Stockgrowers of America: Fighting for the U.S. Cattle Producer
3. United States, Canada and Mexico Agree to Mutual Assistance During Public Health Emergencies
4. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
5. Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
6. A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than in Europe
7. American Oriental Bioengineering to Initiate a Phase One Clinical Trial in the United States of AOBO-001 Oral Capsule
8. Premier Research Expands its Medical Device Operations to the United States
9. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
10. United States Patent and Trademark Office Publishes Stemedicas Patent Application for the Treatment of Diabetic Retinopathy
11. EMD Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb 23, 2017 Research and Markets has ... Analysis and Strategies - 2016" report to their offering. ... The latest research ... drug pricing data and benchmarks in the global Autism Spectrum Disorder ... What are the key drugs marketed for Autism Spectrum ...
(Date:2/23/2017)... -- ITL Limited, ( ASX: ITD ), an innovative diversified healthcare ... ended 31 December 2016 compared with the previous corresponding period. A ... here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: 1.2 ... $15.7m; up 11%) Profit before tax of $2.12m ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Analysis and Strategies - 2016" report to their offering. ... The latest research ... pricing data and benchmarks in the global Oesophageal Cancer market. ... What are the key drugs marketed for Oesophageal Cancer and ...
Breaking Medicine Technology:
(Date:2/23/2017)... Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... first two episodes of WE TV’s “Mama June: From Not to Hot,” which will ... TV notable, “Mama” June Shannon, known to millions from the 2012 reality television series, ...
(Date:2/23/2017)... IPSWICH, Mass. (PRWEB) , ... February 23, 2017 ... ... chosen as an approved content provider for the National Institute for Health ... care and social care-related organizations in the National Health Service (NHS) to search, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink ... publication where generations converge and explore the world from different perspectives. By providing ... enables readers to gain understanding, increase empathy, and find greater happiness. , ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... the pre-eminent publication and community for those in the fight against cancer, has ... important in their success. HRA will release top-line findings in a webinar, ...
(Date:2/23/2017)... ... ... CALNOC, the nation’s first and only nursing quality indicators database today announced ... and Collaboration – in Seattle, WA on October 23, 2017. , Dr. Gary Kaplan ... Seattle since 2000. In addition to his role at Virginia Mason, Dr. Kaplan also ...
Breaking Medicine News(10 mins):